3 Psychedelic Stocks to Invest In the Future of Medicine

InvestorPlace – Stock Market News, Stock Advice & Trading Tips

Psychedelic drugs are going mainstream fast, with research supporting their effectiveness in alleviating emotional problems. Scientists continue to revisit different psychedelics such as LSD, magic mushrooms and other therapeutics for a range of mental ailments. Research is in full swing with the announcement from Johns Hopkins on its development of the Center for Psychedelic and Consciousness Research. With a $17 million commitment for planned studies, the research will further help in normalizing psychedelics. Therefore, the shroom boom has well and truly arrived, and investors should seriously consider adding psychedelic stocks to their portfolios.

Investor interest in psychedelics is on the rise as high-profile executives and celebrities are investing in the sector’s future. With such much interest in alternative psychedelic medicine, analysts believe that the sector could bring in over $6.85 billion by 2027. However, government support and widespread legalization are essential for its rapid advancement. With the recent legalization of psychedelics in various states, it won’t be long when they line up pharmacy aisles.

It is imperative to invest in psychedelic stocks that are needle-movers having the most potential for sustained success. Here are three that stand out right now:

  • Champignon Brands (OTCMKTS:SHRMF)
  • Mind Medicine (OTCMKTS:MMEDF)
  • Hollister Biosciences (OTCMKTS:HSTRF)

Psychedelic Stocks to Buy: Champignon Brands (SHRMF)

Source: local_doctor / Shutterstock.com

Champignon Brands is among the first movers in the psychedelic medicine field and it completed its IPO earlier this year. It is engaged in the production of novel medications, specifically medicinal mushroom products, which aim to treat a variety of mental health problems. It boasts one of the strongest research teams led by its Special Advisory Committee, working diligently to provide high-quality data to its production team. Hence, SHRMF stock is among the hottest investments in the burgeoning psychedelics field.

It has been a busy 2020 for the Vancouver-based company. In April, it announced that it would be acquiring clinic operator AltMed Capital Corp, aiming at opening several subspecialty therapeutic clinics across the U.S. Additionally, the deal also provides several intellectual properties in developing novel medicines. Moreover, Champignon is also looking to open clinics for psychedelics, such as ketamine, psilocybin and MDMA throughout the North American continent.

It has six current trials in Phase I and pre-clinical stages collectively and seven patents pursuing ketamine/psilocybin solutions. To better reflect its scientific alignments, it is proposing a name change to Apotheosis Scientific Ltd. Therefore, with so much on its plate, the company can become a juggernaut among psychedelic stocks.

Mind Medicine (MMEDF)

Business psychology concept and wealth thinking

Source: Shutterstock

MindMedicine is one of the largest biotechs involved in psychedelic drugs’ clinical development tackling mental health troubles. With the success of its Compass Pathways IPO, it is now looking to enlist on the U.S. stock exchange. It would become the second pure-play to be listed on Nasdaq. Hence, MMEDF stock is one of the top investments in the sector with massive potential.

It has three on-going clinical trials, which can be major

Read more

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

NEW YORK, Nov. 24, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.

Digital therapeutics are defined as evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease. Pairing digital tools, such as wearables and the latest in machine learning, with psychedelic assisted therapies, can give healthcare providers the ability to optimize and better understand the patient journey and therapeutic outcomes from pre-care through to after-care.

MindMed Co-Founder and Co-CEO J.R. Rahn said, “We believe that the next frontier in psychedelic medicine will be to quantify with great precision psychedelic assisted therapy’s impact on patient populations. This new division will not only build apps, technologies and other platforms to help the patient, but hopefully also make the medical community comfortable with this novel treatment paradigm for mental health and addiction by measuring the potential value to their patient populations and ultimate savings to insurers.”

Recent advancements in digital therapeutics have the potential to enable a real time assessment of efficacy in both clinical trials and real-world settings leading to a more robust understanding of the value of a treatment and long-term impact on patient outcomes.

MindMed’s clinical team under the leadership of President and Head of Clinical Dr. Miri Halperin Wernli is designing an experimental clinical trial that pairs non-hallucinogenic psychedelic inspired medicines such as microdoses of LSD with digital therapeutics to track, engage and influence patient behavior. MindMed intends to announce full details of this clinical trial once MindMed and its scientific collaborators finalize the protocol design for submission to relevant health regulators.

Dr. Miri Halperin Wernli said, “This is a perfect moment for digital medicine solutions to come to patients to help support behavioral change, measure and enhance psychiatric care and health outcomes. Our intention is to use digital therapeutics alongside pharmaceutical medicines to maximize one another’s value to the patient and for the healthcare system. The two classes of medicine, along with psychotherapy and various forms of cognitive behavioral therapies, must be regarded as complementary to enhance outcomes, which will create new opportunities to improve quality of care and patient outcomes and drive behavior change at scale.”

About MindMed

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to the company’s groundbreaking approach to developing the next-generation of psychedelic inspired medicines and therapies.

MindMed trades on the Canadian

Read more

DC ballot initiative could decriminalize psychedelic plants, like magic mushrooms, in the city

This Election Day, voters in Washington, D.C., will consider a measure that, if approved, would effectively decriminalize the use of psychedelic plants, like ayahuasca and psilocybin mushrooms, more commonly known as magic mushrooms.

Initiative 81, or the Entheogenic Plant and Fungus Policy Act of 2020, would make the investigation and arrest for adult cultivation and use of psychedelic plants one of the lowest law enforcement priorities for the district’s police department. It also contains a non-binding clause asking the D.C. attorney general to not prosecute anyone charged with an offense related to the substances.

Melissa Lavasani, a mom and D.C. government employee who proposed the initiative, called the measure a “small step” toward ending the war on drugs.

“We believe that there is a growing body of research around these substances, and there’s a lot of interest in the research community,” she said. “And our laws should adapt to what the research has indicated.”

The district would follow Denver, Oakland, California and Santa Clara, California, in decriminalizing some or all psychedelic plants. Voters in Oregon are also considering a similar measure, which would set up treatment facilities using psilocybin mushrooms, but would not decriminalize them.

Lavasani saw the success of the decriminalization campaign in Denver and began advocating for a similar measure in the district. She knew the therapeutic value of psychedelics personally after using psilocybin mushrooms and ayahuasca to treat severe postpartum depression.

PHOTO: A vendor poses with harvested psilocybin mushrooms, May 19, 2019 in Denver.

A vendor poses with harvested psilocybin mushrooms, May 19, 2019 in Denver.

“I had zero experience with depression or any real mental health issues,” Lavasani said. “I’ve had a pretty regular, good life. And I had never been in that situation before and I was struggling terribly.”

At the time, she sought a more natural way of treating depression (through cognitive behavioral therapy and other methods), but nothing was working for her.

“At that point in time, I was contemplating suicide because I was so miserable, and my family was really suffering with me,” she said. “I didn’t really see a way out.”

Then, Lavasani came across an interview with mycologist Paul Stamets on the Joe Rogan podcast, in which Stamets talked about the therapeutic benefits of psilocybin mushrooms. After doing her own research, Lavasani decided to try them.

“I would take it in the morning and within a matter of days I started to get my humanity back,” she said. “I started to feel like I used to. I was engaging with my children and I was engaging with my husband again, and the whole world lit up for me.”

But despite how much her mental health improved, the fear of being arrested for using the Schedule I drug persisted.

“It’s a frightening thought to work your entire life for your career and to build your family and to know that it can all be wiped out with one person finding this information out and reporting it to the police,” Lavasani said. “I

Read more

Ehave Expands Its Psychedelic Mental Health Platform with Medchart, a Leader in Medical Record Software, as a Plugin to the Ehave Dashboard

Ehave partners with world-renowned tech platform, Medchart. The Medchart plugin will allow medical professionals using the Ehave Dashboard to easily transfer medical records, while allowing patients to own their own data and do what they want with it.

MIAMI, Oct. 20, 2020 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to healthcare patients, announced today it has added Medchart, the only comprehensive solution for medical record exchange, as the first plugin to its Ehave Dashboard. This will not only allow patients to take more control over their psychedelic medical records, it will allow patients to access innovative treatments to mental health by providing clinicians and pharmaceutical companies with data that will make the provision of care more readily available. The combination of Medchart with the Ehave Dashboard will help provide a dataset that can be used to clinically validate some of these more experimental forms of therapy including psychedelics and ketamine treatment.

Personal Health Records (PHR) are a patient’s individualized collection of their health records. By allowing patients to own their own records, medical professionals and psychedelic researchers can begin working with patients to create biomarkers on the how they can live a longer healthier life, as well as what treatments are effective. Giving data to the PHR helps doctors who can prescribe medicine based on your data. As you add sensors into the dashboard you can add more data in your PHR. There are 11 million Americans who are resistant to most mental health therapies, and they can cost the healthcare system as much as $250 billion. Since major pharmaceutical companies don’t develop drugs for them, the Ehave Dashboard could potentially aggregate data from this patient population and provide that data to drug developers for clinical trials. This data could also help insurers route patients to the treatment providers who can help them the most.

Toronto-based Medchart, which enables the electronic transfer of medical records through express patient consent, simplifies the request of health information for patients. Medchart digitizes the exchange of health information between healthcare providers, attorneys, insurers, payers, researchers and patients while improving transfer speed, data quality, and business insights through artificial intelligence and machine learning. The company provides cloud based medical record solutions across North America with purpose-built solutions for personal injury and mass tort attorneys in the United States. Medchart complies with all federal and provincial privacy legislation including HIPAA, PIPEDA, PHIPA, PIPA, PHIA, HIA, and more.

The Ehave Dashboard is a data driven platform that has been strategically developed to provide better communication among medical practitioners and health care providers. The aggregation of data and information into one application has proven effective in streamlining the health process for both patients and providers. The Ehave Dashboard has been developed through years of testing with mental healthcare professionals at one of Canada’s largest hospitals, The Hospital for Sick Children in Ontario. In addition to providing better outcomes, the proprietary platform allows individuals to

Read more